Retatrutide is a synthetic single-chain peptide engineered so that one molecule can bind three distinct incretin-family receptors — GIP, GLP-1, and glucagon.
Structural strategy
Achieving triple activity requires a sequence that blends recognition motifs for all three receptors while preserving stability. Like other long-acting research agonists, it carries a fatty-acid side chain (acylation) that promotes reversible albumin binding to slow clearance in models — the same half-life-extension idea used in tirzepatide and semaglutide.
How it is made
Production relies on solid-phase peptide synthesis followed by side-chain conjugation, cleavage, and chromatographic purification, with HPLC and mass spectrometry confirming purity and identity.
Product page: Retatrutide research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.